Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.

This disclosure relates to antigenic OspA polypeptides and their use in eliciting antibodies against OspA. Also disclosed are antigenic polypeptides comprising an OspA polypeptide and a ferritin protein.

The invention pertains to a vaccine comprising in combination non-replicating immunogens of Erysipelothrix rhusiopathiae, porcine parvo virus, Leptospira interrogans and live attenuated PRRS virus, and a pharmaceutically acceptable carrier, for use in a method for prophylactic treatment of a swine against an infection with Erysipelothrix rhusiopathiae, porcine parvo virus, Leptospira interrogans and PRRS virus, wherein the vaccine is administered in a single dose with regard to the treatment against an infection with PRRS virus.

The present invention provides new pharmaceutical and vaccine compositions comprising Treponema spp. bacterins, supplemented with antigens from Treponema spp. or other digital dermatitis causative pathological agents such as but not limited to D. nodosus or F. necrophorum, for effectively immunizing susceptible mammals, preferably ungulates, against DD, in particular against bovine digital dermatitis. The present invention also identifies Treponema pedis and Treponema phagedenis as two of the etiologic agents of digital dermatitis (DD) in mammals, in particular ungulate digital dermatitis. The invention therefore also provides isolated cultures of Treponema pedis and Treponema phagedenis for effectively immunizing susceptible mammals, preferably ungulates, against DD, in particular against bovine digital dermatitis. In addition, the present invention provides methods of diagnosing DD by detecting infection with a series of specific Treponema antigens.

A complementary DNA (cDNA) with SEQ ID NO: 1 which encodes an immunogenic fragment of major outer sheath protein (Msp) of Treponema denticola.

The present invention relates to Brachyspira hyodysenteriae strains and their use in diagnosis or treatment. In addition, the invention provides a vaccine against diarrheal disease, in particular swine dysentery.

Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject.

Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition

This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.

The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.